AbbVie Gastroenterology
AbbVie has been working to advance standards of care in gastroenterology for more than 10 years. Our expertise and dedication coupled with our drive for innovation creates a brighter future for patients.
A Legacy of Innovation
We have taken bold steps to shape the landscape in inflammatory bowel disease (IBD) management, striving to help patients achieve a better tomorrow. But we have more work to do. We are relentless in our quest to better understand patient needs and will continue to work closely with patients and partners to advance the quality of care in IBD.
Pioneers in Science
Leaving No Patient Behind
As we learn more about pathophysiology and optimal disease management we can set more ambitious goals for tackling IBD in ways that extend beyond symptoms.
Addressing Unmet Needs
We currently have ongoing / planned trials in IBD. By learning, adapting and innovating, AbbVie aspires to make IBD patients’ long-term goals possible.
Partnerships with Purpose
We work with partners to tackle global challenges in IBD and shape the future of disease management. Together, we aim to enhance quality of care by educating on Treat to Target (T2T), demonstrating its clinical and economic impact, and making non-invasive monitoring standard for most patients.
IE-SKZG-250081 | Date of preparation: January 2026
